Weekly HIV Pill Works as Well as Daily Treatment

Imagine taking your HIV medication once a week instead of every single day. That possibility just moved closer to reality for millions of people.

New research presented at the AIDS 2026 conference in Rio de Janeiro shows a once-weekly HIV pill works just as well as current daily treatments. The pill combines two antiretrovirals called islatravir and lenacapavir into a single weekly dose.

Two major studies called ISLEND-1 and ISLEND-2 tested the weekly pill on over 1,200 people already doing well on daily HIV treatment. Researchers switched about half of each group to the weekly pill and tracked their progress for 48 weeks.

The results were impressive. In ISLEND-1, zero people on the weekly pill had detectable virus levels after 48 weeks. In ISLEND-2, only one person on the weekly pill showed detectable virus levels compared to four on daily treatment.

Over six million South Africans currently take daily HIV medication in the form of a single tablet. Most take a combination of dolutegravir, lamivudine or emtricitabine, and tenofovir.

Professor Francois Venter from the University of the Witwatersrand called the weekly pill "the next treatment blockbuster." He wasn't involved in the studies but sees huge potential for patients and healthcare systems.

The Ripple Effect

The benefits extend far beyond individual convenience. Healthcare facilities could dispense six months of medication using the same number of tablets previously needed for just one month.

The weekly pill appears cheap to manufacture, making it promising for low and middle-income countries. It doesn't require the complex supply chains or extensive healthcare worker training that injectable medications need.

Patients have been asking for less frequent dosing for years. Remembering to take a pill every single day can be exhausting, especially when you're managing other aspects of life and health.

The weekly pill was well-tolerated in both studies, though some participants reported mild treatment-related side effects. These studies will continue for another 48 weeks to confirm the long-term safety and effectiveness.

One component of the weekly pill, lenacapavir, is already being used in six-monthly HIV prevention injections rolling out at about 10% of public clinics in South Africa. This means healthcare systems already have some familiarity with the medication.

The research represents real progress toward ending the HIV epidemic by making treatment easier to stick with over the long term.